Stockreport

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

Solid Biosciences Inc.  (SLDB) 
Last solid biosciences inc. earnings: 8/14 07:25 am Check Earnings Report
US:NASDAQ Investor Relations: investors.solidbio.com/investor-relations
PDF - Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation - CHARLESTOWN, Mass., Jan. 21, 20 [Read more]